Egetis recruits Laetitia Szaller as General Counsel and Head of Compliance
December 22, 2023
Stockholm, Sweden, December 22, 2023. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced the recruitment of Laetitia Szaller as General Counsel and Head of Compliance. Laetitia will be a member of the Company’s Executive Leadership Team, and report to the CEO Nicklas Westerholm.
Laetitia has over 16 years of experience in the pharmaceutical sector. She holds dual qualifications to practice law in both the UK and Belgium, reflecting her international scope and ability to navigate complex, multi-jurisdictional operations. Her career has spanned across various sectors including pharma, medical devices, and the automotive industry, where she has managed global legal and compliance departments.
Prior to joining Egetis Laetitia was General Counsel and VP Business Development at AM Pharma in the Netherlands. She was a member of the senior leadership team, overseeing both legal and compliance operations, business development activities, as well as Company secretary. Before that Laetitia worked at UCB, where she led significant projects in the US, EU, UK, and Asia as an Associate General Counsel. She started her career in the pharmaceutical sector at Abbott and has also worked at Zoetis.
Nicklas Westerholm, CEO of Egetis, commented: “I’m delighted to welcome Laetitia to Egetis and proud that we have been able to attract such a talented and experienced General Counsel to our Company. Laetitia’s experience in successfully leading corporate Compliance operations will also be invaluable for Egetis, as we continue our journey aiming at bringing the first treatment for MCT8 deficiency patients to the market.”